pharma

Cipla

CIPLA · Nifty 50

1,350.8

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

ValuationPE 29.0 (67%ile of 5Y range 20-45). Trading near median.
Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score80/100 (STRONG). 1 positive flags, 1 concerns.
Historical Context154 similar technical setups. Average outcome: -7.2% decline. 0% positive.
Revenue TrendRevenue declining at -2.1% YoY. Revenue declining — -2.1% YoY

Fundamental

80/100

STRONG

Trust

95/100

Verification

Coverage

89/100

HIGH

Quick Take

Cipla scores 80/100 on fundamentals (strong). Cipla: PE above historical average. BROAD EXPANSION regime.

Fundamental Score: 80/100 · STRONG · 1 signals detected

DuPont Analysis

ROE 10.9% broken into three drivers. Each shows how efficiently the company generates returns.

ROE10.9%=
14.0%Net Margin
×
0.6xTurnover
×
1.2xLeverage

ROE of 10.89% is moderate margin-driven and stable. Net margin of 14.0% × asset turnover of 0.63x × leverage of 1.2x.

What This Means

Net margin of 14.0% means the company keeps ₹14.0 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.63x means the company efficiently uses its assets to generate revenue. Leverage of 1.2x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

65.6%

Operating

18.4%

Net

14.0%

declining

Gross margin 65.6% → operating margin 18.4% → net margin 14.0%. Margins are DECLINING. Check if input costs are rising or competition is pressuring pricing.

Financial Health

Earnings Quality

ADEQUATE

Cash flow covers net income 1.1x — earnings are ADEQUATE quality. Cash conversion is reasonable.

Debt Sustainability

COMFORTABLE

Interest covered 89.3x — very comfortable. Debt service is not a concern. Debt/EBITDA at 0.1x is low — balance sheet has capacity.

Free Cash Flow

MODERATE

FCF margin at 3.2% — moderate. Generating cash after investments.

Peer Comparison

Cipla is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹1418 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹1283 (-5%)

Further downside risk

🟡

PE reverts to 5Y median of 28.9

Valuation normalization

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

➡️ Leverage Slowly Rising: Debt growing faster (40.1%) than equity (10.4%)

Risk Flags

🔴 1 Critical1 Positive2 total flags
🔴Cash covers only 15% of current liabilities
Balance Sheet

Liquidity squeeze. Company may struggle to meet short-term obligations without refinancing.

Minimal unusual items — clean earnings
Earnings Quality

Profits are from core operations, not one-offs. High quality.

⚠️ 1 critical + 0 warning flags. Exercise caution.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
Our margin analysis (declining) matches news reports of cost/margin pressure

50 articles scanned for fundamental themes

Facts

P/E Ratio
29.0HIGH
P/B Ratio
3.3HIGH
ROE
11.7%HIGH
Market Cap
₹11224202.6L CrHIGH
From 52W High
81% of high
Promoter Holding
34.6%MODERATE
Institutional
44.2%
Sector Peers
10
Cipla Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight